The truth will make you free.
Appreciate your comments. I take it when you you say generic (the word has sort of a bad ring to it since Bolar) you mean my comment is a generalization. Quite right, any statement involving human decision, BP's in this case, is a generalization, because it is subject to change at any time. If you read my post you will note my qualifier at this time. Please do not be confused by what is in fact the norm in the industry with what both of us would consider better solutions involving some of the factors you bring up. If you or others doubt the validity of the picture as I paint it, I suggest you re read the White Paper. Since it is long, to save you time, I direct you to pages 25 and 26 which spell this out in very easy to understand words.
The fact NVS is willing to spend all that time and money on a cell culture facility is not IMHO an endorsement fo GTCB. It means they are commiting to business as usual.
Market Data 
Markets 
AI
